Natriumglycerophosphat-Ampulle Fresenius (Sodium Glycerophosphate Pentahydrate)

Sodium glycerophosphate pentahydrate, the active ingredient in Natrumglycerophosphat-Ampulle Fresenius, is a phosphate solution presented as an injectable solution for intravenous use. It provides phosphate and sodium ions to correct deficiencies, particularly in patients requiring parenteral nutrition or those with low serum phosphate levels.

GNH USA supplies Natrumglycerophosphat-Ampulle Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide. The product meets EU quality standards and is packaged for sterile administration.

Natrumglycerophosphat is used to manage conditions related to phosphate deficiency and metabolic balance.

- Hypophosphatemia: restores serum phosphate levels in patients with low phosphate. - Parenteral nutrition: supplies essential phosphate as part of total nutrient admixtures. - Metabolic alkalosis: acts as a buffering agent to correct acid‑base disturbances.

Sodium glycerophosphate may cause a range of adverse reactions, most of which are related to electrolyte shifts or local injection responses.

Common Side Effects: - Hyperphosphatemia: elevated serum phosphate levels. - Hypocalcemia: reduced calcium concentration secondary to phosphate binding. - Injection site pain or erythema. - Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Calcium‑phosphate precipitation leading to tissue calcification. - Severe hypotension or cardiovascular instability. - Anaphylactic or severe allergic reaction. - Cardiac arrhythmias due to electrolyte imbalance. - Exacerbation of renal failure in susceptible patients.

When using Natrumglycerophosphat, clinicians should observe several safety measures to minimize risks.

- Serum phosphate monitoring: check levels before and during therapy. - Renal function assessment: avoid rapid infusion in severe renal impairment. - Calcium compatibility: do not mix with calcium‑containing solutions. - Infusion rate: administer over the recommended period to prevent abrupt electrolyte shifts. - Pregnancy and lactation: use only if the expected benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium glycerophosphate can interact with other agents that affect phosphate balance or form insoluble complexes.

Major Interactions (Avoid): - Calcium salts: risk of insoluble calcium‑phosphate precipitation. - Magnesium salts: may precipitate and reduce drug efficacy. - Aluminum‑containing antacids: can bind phosphate and diminish availability.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase urinary phosphate loss, may require dose adjustment. - Vitamin D analogues: enhance phosphate absorption, monitor serum levels. - ACE inhibitors: may alter renal handling of phosphate, requiring observation.